Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for Spyre Therapeutics (SYRE) over the last 10 years, with Q3 2025 value amounting to $99.2 million.

  • Spyre Therapeutics' Change in Acquisitions & Divestments rose 2750.63% to $99.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $340.0 million, marking a year-over-year increase of 6804.55%. This contributed to the annual value of $246.0 million for FY2024, which is 51645.86% up from last year.
  • Spyre Therapeutics' Change in Acquisitions & Divestments amounted to $99.2 million in Q3 2025, which was up 2750.63% from $106.9 million recorded in Q2 2025.
  • In the past 5 years, Spyre Therapeutics' Change in Acquisitions & Divestments ranged from a high of $106.9 million in Q2 2025 and a low of $3.2 million during Q2 2023
  • In the last 5 years, Spyre Therapeutics' Change in Acquisitions & Divestments had a median value of $30.7 million in 2021 and averaged $42.8 million.
  • As far as peak fluctuations go, Spyre Therapeutics' Change in Acquisitions & Divestments crashed by 8700.0% in 2023, and later surged by 168080.0% in 2024.
  • Spyre Therapeutics' Change in Acquisitions & Divestments (Quarter) stood at $22.9 million in 2021, then decreased by 19.26% to $18.5 million in 2022, then increased by 2.16% to $18.9 million in 2023, then skyrocketed by 230.94% to $62.5 million in 2024, then surged by 58.58% to $99.2 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $99.2 million for Q3 2025, versus $106.9 million for Q2 2025 and $71.4 million for Q1 2025.